391 related articles for article (PubMed ID: 33910878)
21. Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study.
Shindo T; Maehana T; Tanaka T; Hashimoto K; Kobayashi K; Takahashi A; Hotta H; Kunishima Y; Taguchi K; Tachiki H; Ito N; Matsukawa M; Kato R; Miyamoto S; Hinotsu S; Masumori N
Int J Urol; 2022 Sep; 29(9):1010-1016. PubMed ID: 35654444
[TBL] [Abstract][Full Text] [Related]
22. Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Yumioka T; Honda M; Shimizu R; Teraoka S; Yamaguchi N; Kawamoto B; Iwamoto H; Morizane S; Hikita K; Takenaka A
Anticancer Res; 2021 Nov; 41(11):5767-5773. PubMed ID: 34732450
[TBL] [Abstract][Full Text] [Related]
23. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of chemotherapy with or without anti-PD-1 for the first-line treatment of advanced urothelial carcinoma.
Han F; Wu Z; Chen J; Liu M; Hu Y
Cancer Med; 2023 Dec; 12(23):21129-21137. PubMed ID: 37990780
[TBL] [Abstract][Full Text] [Related]
25. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
Mollica V; Tassinari E; Santoni M; Marchese PV; Giunchi F; Maloberti T; Tateo V; Ricci C; Rosellini M; Marchetti A; Fiorentino M; Biase D; Massari F
Pathol Res Pract; 2024 Jan; 253():155008. PubMed ID: 38103361
[TBL] [Abstract][Full Text] [Related]
26. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
[TBL] [Abstract][Full Text] [Related]
27. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Massari F; Santoni M; Takeshita H; Okada Y; Tapia JC; Basso U; Maruzzo M; Scagliarini S; Büttner T; Fornarini G; Myint ZW; Galli L; Souza VC; Pichler R; De Giorgi U; Gandur N; Lam ET; Gilbert D; Popovic L; Grande E; Mammone G; Berardi R; Crabb SJ; Kemp R; Molina-Cerrillo J; Freitas M; Luz M; Iacovelli R; Calabrò F; Tural D; Atzori F; Küronya Z; Chiari R; Campos S; Caffo O; Fay AP; Kucharz J; Zucali PA; Rinck JA; Zeppellini A; Bastos DA; Aurilio G; Mota A; Trindade K; Ortega C; Sade JP; Rizzo M; Fiala O; Vau N; Giannatempo P; Barillas A; Monteiro FSM; Dauster B; Mennitto A; Nogueira L; de Carvalho Fernandes R; Seront E; Aceituno LG; Grillone F; Cutuli HJ; Fernandez M; Bassanelli M; Kopp RM; Roviello G; Abahssain H; Procopio G; Milella M; Kopecky J; Martignetti A; Messina C; Caitano M; Inman E; Kanesvaran R; Herchhorn D; Santini D; Bamias A; Bisonni R; Mosca A; Morelli F; Maluf F; Soares A; Nunes F; Pinto A; Zgura A; Incorvaia L; Ansari J; Zabalza IO; Landmesser J; Rizzo A; Mollica V; Marchetti A; Rosellini M; Sorgentoni G; Battelli N; Buti S; Porta C; Bellmunt J
Cancer Immunol Immunother; 2024 Apr; 73(6):106. PubMed ID: 38634928
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
Kanai K; Kikuchi E; Ohigashi T; Miyajima A; Nakagawa K; Nakashima J; Oya M
Int J Clin Oncol; 2008 Dec; 13(6):510-4. PubMed ID: 19093178
[TBL] [Abstract][Full Text] [Related]
29. Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.
Chen Y; Guan Y; Wang J; Ma F; Luo Y; Chen S; Zhang P; Li Q; Cai R; Li Q; Mo H; Lan B; Chen X; Zhao W; Xu B; Fan Y
Int J Cancer; 2020 Dec; 147(12):3490-3499. PubMed ID: 32588429
[TBL] [Abstract][Full Text] [Related]
30. The Combination of Gemcitabine, Cisplatin, and Paclitaxel as Salvage Chemotherapy for Advanced Urothelial Carcinoma.
Hirata T; Hanamoto M; Ogura K; Hayashi N; Takamura K; Edamura K; Ebara S; Saika T
Acta Med Okayama; 2018 Apr; 72(2):175-179. PubMed ID: 29674766
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.
Kaya AO; Coskun U; Ozkan M; Sevinc A; Yilmaz AU; Gumus M; Unal OU; Ozdemir NY; Alici S; Berk V; Degerli H; Oner MK; Ozturk C; Kefeli U; Camcı C;
Onkologie; 2012; 35(10):576-80. PubMed ID: 23038228
[TBL] [Abstract][Full Text] [Related]
32. The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
Giannatempo P; Pond GR; Sonpavde G; Raggi D; Naik G; Galsky MD; Bellmunt J; Necchi A
Eur Urol; 2016 Apr; 69(4):624-633. PubMed ID: 26497923
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
Shindo T; Hashimoto K; Takahashi A; Miyamoto S; Kunishima Y; Sato S; Fukuta F; Hiyama Y; Takayanagi A; Kato R; Wanifuchi A; Ueki Y; Okada M; Adachi H; Kobayashi KO; Tanaka T; Masumori N;
Anticancer Res; 2024 Mar; 44(3):1271-1279. PubMed ID: 38423657
[TBL] [Abstract][Full Text] [Related]
34. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
[TBL] [Abstract][Full Text] [Related]
35. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma.
Suyama T; Ueda T; Fukasawa S; Imamura Y; Nakamura K; Miyasaka K; Sazuka T; Egoshi K; Nihei N; Hamano M; Ichikawa T; Maruoka M
Jpn J Clin Oncol; 2009 Apr; 39(4):244-50. PubMed ID: 19211575
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R
J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].
Albers P; Park SI; Niegisch G; Fechner G; Steiner U; Lehmann J; Heimbach D; Heidenreich A; Fimmers R; Siener R;
Ann Oncol; 2011 Feb; 22(2):288-94. PubMed ID: 20682548
[TBL] [Abstract][Full Text] [Related]
38. Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Uchimoto T; Fukushima T; Komura K; Fukuokaya W; Adachi T; Hashimoto T; Yoshizawa A; Nakamura K; Yano Y; Nishimura K; Nishio K; Nakamori K; Iwatani K; Yamamoto S; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Kimura T; Ohno Y; Shiroki R; Egawa S; Azuma H
BJU Int; 2023 Apr; 131(4):477-485. PubMed ID: 36098556
[TBL] [Abstract][Full Text] [Related]
39. Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma.
Hosogoe S; Hatakeyama S; Kusaka A; Hamano I; Iwamura H; Fujita N; Yamamoto H; Tobisawa Y; Yoneyama T; Yoneyama T; Hashimoto Y; Koie T; Ohyama C
Eur Urol Focus; 2018 Dec; 4(6):946-953. PubMed ID: 28753881
[TBL] [Abstract][Full Text] [Related]
40. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]